Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE-Stroke I: Evolocumab vs Statin Monotherapy in Thrombolysed Non-LVO Ischemic Stroke
ChiCTR2600125072Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in ischemic stroke comparing Control group – statin-based standard of care with Intervention group – evolocumab plus standard of care (2 arms). Primary endpoint: Functional independence at 90 days. Started May 2026; status: recruiting.
02
Drugs
evolocumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600125072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125072.